Positive EMA Decision for BioArctic's New Drug Candidate

Bioarctic's drug candidate for multiple system atrophy, exidavnemab, is recommended to be classified as an orphan drug, according to the European Medicines Agency (EMA).

Nordic Regulatory experts: Improving biotech chances of Succ

Why is it that so many biotech companies fail? And what are the tools needed to change that fact?

”The importance of stratification in a statistician’s August kitchen”

Ingrid Lönnstedt writes about an experiment of her own at home and about what lessons can be learned from it, in a science column.

From Valneva to the CEO position at NorthX – “I saw it as a great opportunity”

A new cell therapy for leukaemia, a vaccine in tablet form against cholera, and a proprietary mRNA line with the potential capacity to supply the entire Nordic ...

Anna Törner: ”Mom, do you think you’ll ever get married again?”

”I realize I’m slowly descending into that familiar statistical rabbit hole, where life’s biggest uncertainties are reduced to point estimates and confidence in...

Getinge and Neobiomics received Swecare's export awards

Two companies received awards during Swecare's annual conference.

“Conducting research at universities is becoming more and more like working at a research hotel”

The government wants Swedish research to focus on excellence and innovation, but can the two be combined? Life Science Sweden talks to Anna Falk, a professor at...

“A major energy boost for the entire cancer vaccine field”

The development of cancer vaccines has accelerated in recent years. Norwegian Ultimovacs is one of the companies attempting to develop a new type of treatment l...

Ingrid Lönnstedt: ”The confidence interval and its width”

Always keep an eye on the width of your and others’ confidence intervals, writes Ingrid Lönnstedt in a science column.

Biobank Sverige får miljontillskott i satsning på kliniska prövningar

Biobank Sverige tilldelas tio miljoner kronor som en del av etableringen av Swetrial, ett nytt nationellt kansli med uppdrag att stärka Sveriges position inom k...

The top five most expensive drugs in 2025

New advanced therapeutic medicines are reaching the market, but their price tags remain exceptionally high. This year’s ranking of the most expensive drugs in t...

Trygg tryckmätning i hygieniska processer – OEM Automatic erbjuder lösningen från WIKA

I tillämpningar där hygien och säkerhet är avgörande, som inom läkemedelstillverkning och aseptisk livsmedelsproduktion, krävs komponenter som lever upp till de...

ZEISS continues to drive digital era forward in ophthalmology

2 million digitally planned cataract cases in the U.S. alone.

Her company is developing a new tablet form obesity drug

Obesity and diabetes are the primary targets of a new tablet treatment under development by Malmö-based Pila Pharma. The company’s ambition is to take on the bi...

ZEISS showcases comprehensive workflow for full spectrum of retina care at EURETINA

ZEISS Medical Technology combines its diagnostic, surgical and digital technologies to support healthcare professionals in advancing retinal care.

Digitala manometrar för exakt tryckmätning med WIKA

För att uppnå noggranna och tillförlitliga tryckmätningar krävs avancerade mätinstrument som är både robusta och lättanvända. OEM Automatic erbjuder digitala ma...

Business Sweden’s new team is rolling out the blue-yellow carpet

According to Business Sweden’s life science team, the combination of substantial medical know-how and an ever-flourishing tech sector is a success factor for Sw...

16 miljoner kronor till ATMP i Västsverige

Genom en miljonsatsning i Västra Götalandsregionen ska små och medelstora life sciene-bolag få stöd för att accelerera utvecklingen inom avancerade terapiläkemedel (ATMP).

Discover the new ZEISS Axioscan 7 clinical

Your digital slide scanner for diagnostics & clinical research.

Tilly Medical Products AB

Explore our tailored program for Control 2025

Choose an innovation tour, or join our industry-specific guided tours.

Flexibelt och skalbart försäkringsskydd för Life Science-bolag

Vi förstår behovet av att minimera kostnader och samtidigt säkerställa ett heltäckande skydd som är anpassat till den komplexa bransch du verkar i. Att ha rätt ...

FOKUS Patient turns international

FOKUS Patient is arranging conferences over 3 days in October, and this year, the focus will be on international collaborations.

Specific proposals and targets top the universities’ desired priorities

What are the universities’ expectations for the update of the national life science strategy? Life Science Sweden posed the question to representatives from Kar...